Adults 18 to 130, any sex, with Acute Myocardial Infarction or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)Primary· 29 months
Study participants received dapagliflozin 10 mg or matching placebo, given once daily in addition to SoC. Overall, the mean study duration was 12.0 months (time in study until last visit) with an accumulated 4023.9 participant-years. The maximum study duration for any participant was 29 months.
"Number of Events" for NYHA corresponds to the number of participants with a non-missing value for NYHA functional class at the last visit, and that all participants with a non-missing value take part in the analysis comparing their NYHA class value with all other participants with a NYHA value, accord
The hierachical composite endpoint of all components
Group
Value
95% CI
Dapa 10 mg
1990
Placebo
1970
Death, adjudicated
Group
Value
95% CI
Dapa 10 mg
41
Placebo
33
Hospitalisation due to HF
Group
Value
95% CI
Dapa 10 mg
32
Placebo
41
Non-fatal MI
Group
Value
95% CI
Dapa 10 mg
29
Placebo
32
AF/Flutter event
Group
Value
95% CI
Dapa 10 mg
8
Placebo
15
New onset of T2DM
Group
Value
95% CI
Dapa 10 mg
40
Placebo
74
NYHA Classification at last visit, measuring limitations of physical activity
Group
Value
95% CI
Dapa 10 mg
1839
Placebo
1773
Body Weight decrease of at least 5% at last visit
Group
Value
95% CI
Dapa 10 mg
684
Placebo
468
Adverse events — posted to ClinicalTrials.gov
Time frame: Time frame was from date of randomization and up to and including last day in study, up to 29 months..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
· Phase 4
· active not recruiting
Other recruiting trials for Acute Myocardial Infarction
Currently open trials in the same condition.
NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations
· NA
· recruiting
NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial
· Phase 4
· recruiting
NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
· NA
· recruiting
NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
· Phase 4
· recruiting
NCT07522164 — Acute Myocardial Infarction Clinical Cohort
· active not recruiting
Other AstraZeneca trials
Trials by the same sponsor.
NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
· not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential
· not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
· NA
· not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
· Phase 4
· not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04564742.